<p>Arcus Biosciences, Inc.（纽约证券交易所代码：RCUS - 获取免费报告）在周五达到了新的 52 周高点。该公司的股价最高达到 22.44 美元，最后交易价格为 22.3790 美元，交易量为 883816 股。该股票之前的收盘价为 21.23 美元。</p>
<p>获取 <strong>Arcus Biosciences</strong> 的提醒：</p>
<h2>分析师评级变动</h2>
<ul>
<li>从滞后者到领军者：小型股正在崛起</li>
</ul>
<p>多位股票分析师对 RCUS 股票发表了看法。HC Wainwright 将 Arcus Biosciences 的目标股价从 24.00 美元上调至 28.00 美元，并在 10 月 29 日的研究报告中给予该股票 “买入” 评级。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Arcus Biosciences 的 “卖出（d-）” 评级。高盛集团在 10 月 30 日的研究报告中将 Arcus Biosciences 的目标股价从 14.00 美元上调至 16.00 美元，并给予该公司 “中性” 评级。Wedbush 在 10 月 29 日的研究报告中设定了 Arcus Biosciences 的目标股价为 35.00 美元，并给予该公司 “跑赢大盘” 评级。最后，Truist Financial 在 10 月 7 日的报告中重申了 “买入” 评级，并将 Arcus Biosciences 的目标股价设定为 39.00 美元（上调自 32.00 美元）。七位分析师给予该股票 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Arcus Biosciences 目前的共识评级为 “适度买入”，平均目标股价为 28.44 美元。</p>
<p><strong>阅读我们关于 Arcus Biosciences 的最新报告</strong></p>
<h2>Arcus Biosciences 股价上涨 5.6%</h2>
<ul>
<li>MarketBeat 周回顾 – 7/10 - 7/14</li>
</ul>
<p>该公司的流动比率为 3.65，速动比率为 3.65，债务股本比率为 0.22。该公司的市值为 24.2 亿美元，市盈率为-6.50，贝塔值为 0.90。该股票的 50 日简单移动平均线为 16.44 美元，200 日简单移动平均线为 11.88 美元。</p>
<p>Arcus Biosciences（纽约证券交易所代码：RCUS - 获取免费报告）在 10 月 28 日星期二发布了季度财报。该公司报告季度每股收益为（1.27 美元），超出市场共识预期的（1.33 美元）0.06 美元。Arcus Biosciences 的净利润率为-136.40%，股本回报率为-68.17%。该公司季度收入为 2600 万美元，而市场共识预期为 1989 万美元。在去年同期，该公司每股收益为（1.00 美元）。该公司的季度收入同比下降了 45.8%。整体来看，股票研究分析师预测 Arcus Biosciences, Inc.在本财年将发布-3.15 美元的每股收益。</p>
<h2>内部活动</h2>
<ul>
<li>吉利德通过投资 AlloVir 和 Arcus 扩大生物科技足迹</li>
</ul>
<p>在相关消息中，总裁 Juan C. Jaen 在 10 月 29 日星期三出售了 77840 股公司的股票。股票以平均价格 20.90 美元出售，总价值为 1626856.00 美元。出售完成后，总裁持有公司股票 1091374 股，价值约 22809716.60 美元。此次交易使其持股减少了 6.66%。该出售在与证券交易委员会的法律文件中披露，相关信息可通过此链接访问。此外，首席财务官 Robert C. Goeltz II 在 10 月 28 日星期二的交易中出售了 5000 股公司的股票。股票以平均价格 20.00 美元出售，总交易额为 100000.00 美元。交易完成后，首席财务官直接持有公司股票 92138 股，价值 1842760 美元。这代表其持股减少了 5.15%。该出售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士出售了 210875 股公司股票，价值 4017263 美元。当前 9.60% 的股票由内部人士持有。</p>
<h2>机构投资者对 Arcus Biosciences 的看法</h2>
<p>几家机构投资者和对冲基金最近增加或减少了对 RCUS 的持股。高盛集团在第一季度将其在 Arcus Biosciences 的持股增加了 106.2%。高盛集团目前拥有 914208 股公司股票，价值 7177000 美元，此前在上个季度增持了 470755 股。Rhumbline Advisers 在第一季度将其在 Arcus Biosciences 的持股增加了 14.8%。Rhumbline Advisers 目前拥有 182909 股公司股票，价值 1436000 美元，此前在上个季度增持了 23645 股。Woodline Partners LP 在第一季度将其在 Arcus Biosciences 的持股增加了 45.5%。Woodline Partners LP 目前拥有 5127304 股公司股票，价值 40249000 美元，此前在上个季度增持了 1603367 股。Nordea Investment Management AB 在第二季度将其在 Arcus Biosciences 的持股增加了 17.1%。Nordea Investment Management AB 目前拥有 319899 股公司股票，价值 2633000 美元，此前在上个季度增持了 46776 股。最后，VIRGINIA RETIREMENT SYSTEMS ET Al 在第二季度购买了 Arcus Biosciences 的新头寸，价值约 295000 美元。机构投资者和对冲基金持有公司 92.89% 的股票。</p>
<h2>Arcus Biosciences 公司简介</h2>
<p>（获取免费报告）</p>
<p>Arcus Biosciences, Inc.是一家临床阶段的生物制药公司，专注于在美国开发和商业化癌症疗法。该公司的产品管线包括 Domvanalimab，一种抗 TIGIT 抗体，目前处于第二阶段和第三阶段临床试验；以及 AB308，一种正在研究的抗 TIGIT 单克隆抗体，目前处于第一阶段 b 临床试验，研究对象为晚期实体瘤和血液恶性肿瘤患者。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，而不是 Arcus Biosciences</li>
<li>投资旅游股票的好处</li>
<li>Cloudflare 刚刚打破了互联网，但它仍然是一个炙手可热的买入机会</li>
<li>上海证券交易所综合指数是什么？</li>
<li>Anthropic 刚刚成为人工智能领域最热门的项目——得到了微软和 NVIDIA 的支持</li>
<li>如何找到被低估的股票</li>
<li>Affirm 刚刚超越了预期收益——但它能否超越 Klarna 的规模？</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Arcus Biosciences 吗？</h2>
<p>在考虑 Arcus Biosciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Arcus Biosciences 并不在名单上。</p>
<p>虽然 Arcus Biosciences 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

RCUS

<p>Arcus Biosciences（纽约证券交易所代码：RCUS）达到了新的 52 周高点，交易价格为 22.44 美元，成交量为 883,816 股。分析师的评级意见不一：HC Wainwright 和 Truist Financial 给予 “买入” 评级，而 Weiss Ratings 则给予 “卖出” 评级。该公司报告的季度每股收益为（1.27 美元），超出预期。内部人士最近出售了 210,875 股，价值 4,017,263 美元。高盛和 Rhumbline Advisers 等机构投资者增加了他们的持股。Arcus Biosciences 的市值为 24.2 亿美元，净利润率为负 136.40%</p>

<p>Shares of Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) reached a new 52-week high on Friday . The company traded as high as $22.44 and last traded at $22.3790, with a volume of 883816 shares trading hands. The stock had previously closed at $21.23.</p>
<div class="lb-trans"><p>Arcus Biosciences, Inc.（纽约证券交易所代码：RCUS - 获取免费报告）在周五达到了新的 52 周高点。该公司的股价最高达到 22.44 美元，最后交易价格为 22.3790 美元，交易量为 883816 股。该股票之前的收盘价为 21.23 美元。</p>
</div><p>Get <strong>Arcus Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Arcus Biosciences</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>From laggards to leaders: Small caps on the rise</li>
</ul>
<div class="lb-trans"><ul>
<li>从滞后者到领军者：小型股正在崛起</li>
</ul>
</div><p>A number of equities analysts have weighed in on RCUS shares. HC Wainwright upped their price target on shares of Arcus Biosciences from $24.00 to $28.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, October 29th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Arcus Biosciences in a research note on Wednesday, October 8th. The Goldman Sachs Group upped their target price on Arcus Biosciences from $14.00 to $16.00 and gave the company a &#34;neutral&#34; rating in a research note on Thursday, October 30th. Wedbush set a $35.00 price target on shares of Arcus Biosciences and gave the company an &#34;outperform&#34; rating in a research note on Wednesday, October 29th. Finally, Truist Financial reiterated a &#34;buy&#34; rating and set a $39.00 target price (up from $32.00) on shares of Arcus Biosciences in a report on Tuesday, October 7th. Seven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Arcus Biosciences currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $28.44.</p>
<div class="lb-trans"><p>多位股票分析师对 RCUS 股票发表了看法。HC Wainwright 将 Arcus Biosciences 的目标股价从 24.00 美元上调至 28.00 美元，并在 10 月 29 日的研究报告中给予该股票 “买入” 评级。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Arcus Biosciences 的 “卖出（d-）” 评级。高盛集团在 10 月 30 日的研究报告中将 Arcus Biosciences 的目标股价从 14.00 美元上调至 16.00 美元，并给予该公司 “中性” 评级。Wedbush 在 10 月 29 日的研究报告中设定了 Arcus Biosciences 的目标股价为 35.00 美元，并给予该公司 “跑赢大盘” 评级。最后，Truist Financial 在 10 月 7 日的报告中重申了 “买入” 评级，并将 Arcus Biosciences 的目标股价设定为 39.00 美元（上调自 32.00 美元）。七位分析师给予该股票 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Arcus Biosciences 目前的共识评级为 “适度买入”，平均目标股价为 28.44 美元。</p>
</div><p><strong>Read Our Latest Report on Arcus Biosciences</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Arcus Biosciences 的最新报告</strong></p>
</div><h2>Arcus Biosciences Trading Up 5.6%</h2>
<div class="lb-trans"><h2>Arcus Biosciences 股价上涨 5.6%</h2>
</div><ul>
<li>MarketBeat Week in Review – 7/10 - 7/14</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 7/10 - 7/14</li>
</ul>
</div><p>The company has a current ratio of 3.65, a quick ratio of 3.65 and a debt-to-equity ratio of 0.22. The company has a market cap of $2.42 billion, a price-to-earnings ratio of -6.50 and a beta of 0.90. The stock has a 50-day simple moving average of $16.44 and a 200 day simple moving average of $11.88.</p>
<div class="lb-trans"><p>该公司的流动比率为 3.65，速动比率为 3.65，债务股本比率为 0.22。该公司的市值为 24.2 亿美元，市盈率为-6.50，贝塔值为 0.90。该股票的 50 日简单移动平均线为 16.44 美元，200 日简单移动平均线为 11.88 美元。</p>
</div><p>Arcus Biosciences (NYSE:RCUS - Get Free Report) last released its quarterly earnings data on Tuesday, October 28th. The company reported ($1.27) EPS for the quarter, beating the consensus estimate of ($1.33) by $0.06. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The business had revenue of $26.00 million for the quarter, compared to the consensus estimate of $19.89 million. During the same period in the prior year, the firm earned ($1.00) EPS. The business's revenue for the quarter was down 45.8% on a year-over-year basis. As a group, equities research analysts predict that Arcus Biosciences, Inc. will post -3.15 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Arcus Biosciences（纽约证券交易所代码：RCUS - 获取免费报告）在 10 月 28 日星期二发布了季度财报。该公司报告季度每股收益为（1.27 美元），超出市场共识预期的（1.33 美元）0.06 美元。Arcus Biosciences 的净利润率为-136.40%，股本回报率为-68.17%。该公司季度收入为 2600 万美元，而市场共识预期为 1989 万美元。在去年同期，该公司每股收益为（1.00 美元）。该公司的季度收入同比下降了 45.8%。整体来看，股票研究分析师预测 Arcus Biosciences, Inc.在本财年将发布-3.15 美元的每股收益。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><ul>
<li>Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus</li>
</ul>
<div class="lb-trans"><ul>
<li>吉利德通过投资 AlloVir 和 Arcus 扩大生物科技足迹</li>
</ul>
</div><p>In related news, President Juan C. Jaen sold 77,840 shares of the business's stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $20.90, for a total value of $1,626,856.00. Following the completion of the sale, the president owned 1,091,374 shares of the company's stock, valued at approximately $22,809,716.60. The trade was a 6.66% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, CFO Robert C. Goeltz II sold 5,000 shares of the firm's stock in a transaction dated Tuesday, October 28th. The shares were sold at an average price of $20.00, for a total transaction of $100,000.00. Following the completion of the transaction, the chief financial officer directly owned 92,138 shares in the company, valued at $1,842,760. This represents a 5.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 210,875 shares of company stock worth $4,017,263. 9.60% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在相关消息中，总裁 Juan C. Jaen 在 10 月 29 日星期三出售了 77840 股公司的股票。股票以平均价格 20.90 美元出售，总价值为 1626856.00 美元。出售完成后，总裁持有公司股票 1091374 股，价值约 22809716.60 美元。此次交易使其持股减少了 6.66%。该出售在与证券交易委员会的法律文件中披露，相关信息可通过此链接访问。此外，首席财务官 Robert C. Goeltz II 在 10 月 28 日星期二的交易中出售了 5000 股公司的股票。股票以平均价格 20.00 美元出售，总交易额为 100000.00 美元。交易完成后，首席财务官直接持有公司股票 92138 股，价值 1842760 美元。这代表其持股减少了 5.15%。该出售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士出售了 210875 股公司股票，价值 4017263 美元。当前 9.60% 的股票由内部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Arcus Biosciences</h2>
<div class="lb-trans"><h2>机构投资者对 Arcus Biosciences 的看法</h2>
</div><p>Several institutional investors and hedge funds have recently added to or reduced their stakes in RCUS. Goldman Sachs Group Inc. boosted its position in Arcus Biosciences by 106.2% during the first quarter. Goldman Sachs Group Inc. now owns 914,208 shares of the company's stock worth $7,177,000 after acquiring an additional 470,755 shares during the last quarter. Rhumbline Advisers increased its position in shares of Arcus Biosciences by 14.8% during the 1st quarter. Rhumbline Advisers now owns 182,909 shares of the company's stock worth $1,436,000 after purchasing an additional 23,645 shares during the last quarter. Woodline Partners LP lifted its holdings in shares of Arcus Biosciences by 45.5% in the 1st quarter. Woodline Partners LP now owns 5,127,304 shares of the company's stock worth $40,249,000 after acquiring an additional 1,603,367 shares during the last quarter. Nordea Investment Management AB lifted its stake in Arcus Biosciences by 17.1% during the second quarter. Nordea Investment Management AB now owns 319,899 shares of the company's stock worth $2,633,000 after purchasing an additional 46,776 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Arcus Biosciences during the 2nd quarter valued at about $295,000. Institutional investors and hedge funds own 92.89% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近增加或减少了对 RCUS 的持股。高盛集团在第一季度将其在 Arcus Biosciences 的持股增加了 106.2%。高盛集团目前拥有 914208 股公司股票，价值 7177000 美元，此前在上个季度增持了 470755 股。Rhumbline Advisers 在第一季度将其在 Arcus Biosciences 的持股增加了 14.8%。Rhumbline Advisers 目前拥有 182909 股公司股票，价值 1436000 美元，此前在上个季度增持了 23645 股。Woodline Partners LP 在第一季度将其在 Arcus Biosciences 的持股增加了 45.5%。Woodline Partners LP 目前拥有 5127304 股公司股票，价值 40249000 美元，此前在上个季度增持了 1603367 股。Nordea Investment Management AB 在第二季度将其在 Arcus Biosciences 的持股增加了 17.1%。Nordea Investment Management AB 目前拥有 319899 股公司股票，价值 2633000 美元，此前在上个季度增持了 46776 股。最后，VIRGINIA RETIREMENT SYSTEMS ET Al 在第二季度购买了 Arcus Biosciences 的新头寸，价值约 295000 美元。机构投资者和对冲基金持有公司 92.89% 的股票。</p>
</div><h2>Arcus Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Arcus Biosciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.</p>
<div class="lb-trans"><p>Arcus Biosciences, Inc.是一家临床阶段的生物制药公司，专注于在美国开发和商业化癌症疗法。该公司的产品管线包括 Domvanalimab，一种抗 TIGIT 抗体，目前处于第二阶段和第三阶段临床试验；以及 AB308，一种正在研究的抗 TIGIT 单克隆抗体，目前处于第一阶段 b 临床试验，研究对象为晚期实体瘤和血液恶性肿瘤患者。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Arcus Biosciences</li>
<li>Investing in Travel Stocks Benefits</li>
<li>Cloudflare Just Broke the Internet, But It’s Still a Red-Hot Buy</li>
<li>What is the Shanghai Stock Exchange Composite Index?</li>
<li>Anthropic Just Became AI’s Hottest Ticket—Backed by Microsoft and NVIDIA</li>
<li>How to Find Undervalued Stocks</li>
<li>Affirm Just Crushed Earnings—But Can It Outrun Klarna’s Scale?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Arcus Biosciences</li>
<li>投资旅游股票的好处</li>
<li>Cloudflare 刚刚打破了互联网，但它仍然是一个炙手可热的买入机会</li>
<li>上海证券交易所综合指数是什么？</li>
<li>Anthropic 刚刚成为人工智能领域最热门的项目——得到了微软和 NVIDIA 的支持</li>
<li>如何找到被低估的股票</li>
<li>Affirm 刚刚超越了预期收益——但它能否超越 Klarna 的规模？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Arcus Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Arcus Biosciences 吗？</h2>
</div><p>Before you consider Arcus Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Arcus Biosciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcus Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Arcus Biosciences 并不在名单上。</p>
</div><p>While Arcus Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Arcus Biosciences 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Arcus Biosciences（NYSE:RCUS）创下 12 个月新高 - 现在仍然值得购买吗？